Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBITDA Margin: 2009-2025

Historic EBITDA Margin for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -78.57%.

  • China Pharma Holdings' EBITDA Margin rose 1054.00% to -78.57% in Q3 2025 from the same period last year, while for Sep 2025 it was -81.63%, marking a year-over-year increase of 39.00%. This contributed to the annual value of -107.50% for FY2024, which is 6187.00% down from last year.
  • As of Q3 2025, China Pharma Holdings' EBITDA Margin stood at -78.57%, which was down 58.61% from -49.53% recorded in Q2 2025.
  • China Pharma Holdings' EBITDA Margin's 5-year high stood at -13.81% during Q1 2023, with a 5-year trough of -160.40% in Q2 2024.
  • For the 3-year period, China Pharma Holdings' EBITDA Margin averaged around -77.22%, with its median value being -71.36% (2024).
  • As far as peak fluctuations go, China Pharma Holdings' EBITDA Margin slumped by 7,441bps in 2024, and later soared by 11,087bps in 2025.
  • China Pharma Holdings' EBITDA Margin (Quarterly) stood at -28.97% in 2021, then plummeted by 803bps to -37.00% in 2022, then plummeted by 1,447bps to -51.46% in 2023, then tumbled by 7,441bps to -125.87% in 2024, then skyrocketed by 1,054bps to -78.57% in 2025.
  • Its last three reported values are -78.57% in Q3 2025, -49.53% for Q2 2025, and -68.47% during Q1 2025.